Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

Abstract

A dose-dependent reduction in blood eosinophils across all mepolizumab doses investigated was observed. The subcutaneous absolute bioavailability was 74%. The route of administration did not affect the mepolizumab exposure eosinophil response relationship.